|Mr. Roberto Francesco Bellini||Pres, CEO & Director||433.17k||N/A||1980|
|Mr. Ramzi Benamar||Chief Financial Officer||334.24k||N/A||1973|
|Dr. Denis Garceau||Chief Scientific Officer||272.46k||N/A||1957|
|Mr. Francois Desjardins C.A., CPA, CPA, CA||Sr. VP of Fin.||176.85k||N/A||1963|
|Dr. Catherine M. Bonuccelli||Chief Medical Officer||452.83k||N/A||1958|
|Mr. Daniel Matthews||Director of Investor Relations & Communications||N/A||N/A||N/A|
|Mr. Tony Matzouranis||Sr. VP of Bus. Devel.||N/A||N/A||1973|
|Mr. Sebastien Roy||Corp. Sec.||N/A||N/A||1976|
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.
BELLUS Health Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 3; Board: 8; Shareholder rights: 6; Compensation: 8.